These results indicate that adding EB1089 in the combined treatment of lapatinib with antiestrogens enhances the effectiveness of therapies targeting ER and HER2 in HER2-positive breast cancer cells expressing ERα. The gene discussed is ESR1; the disease is breast carcinoma.